Enlivex Ltd. · NASDAQ:ENLV
Enlivex — Bioblast Pharma — Merger or Acquisition (December 2018)
12 slides from Enlivex's merger presentation, Dec 6, 2018
Slide 1: High Doses of ALLOCETRA Resulted in Zero Cases of GvHD Grade II-IV
High Doses of ALLOCETRA™ Resulted In Zero (0) Cases of GvHD Grade II-1V ** Statistically significant results, p-value = 0.0156 = 1.56%, n=13 ** RUS. Historia ‘Averages (CBMTR Database) Cohort 142 (Low ‘acohorts 34 (high doses 40mm ‘as/kg and 210% cals)
Slide 2: ALLOCETRA Reduces Up To 60% Hospitalization Time
Time to firs hosphal discharge (days) Hospitalization Days Post Sone-Marrow TWenspiantation: ALLOCETRA™ Reduces Up To 60% Hospitalization Time (GTR Oatabse) Sem esa a me eb) sober 4 hgh doses: ‘ommend 2mm e/g)
Slide 3: Cytokine profile post bone-marrow transplantation
‘6 concentration (pgim) Cytokine profile post bone-marrow transplantation in 7 patients with ALL, 5 with AML, 1 with CML UNCONTROLLED (mmesanl Aen [ALLOCETRA™ PREVENTS UNCONTROLLED SIGNALING LEVELS (CYTOKINE STORM) POST TRANSPLANTATION ecm Sauna ‘tig ot Anes Boscia Shang onleces
Slide 4: Cytokine profile post bone-marrow transplantation
Cytokine profile post bone-marrow transplantation in 7Tpatients with ALL, 5 with AML, 1 with CML 5 aealeaant i. zi 27 — % “cap = ‘crear eg s ea doe om Simeatang ce ~ nae Rete AUOCETRA™ PREVENTS LUNCONTROUED SIGNALING LEVELS (CYTOKINE STORM) POST TRANSPLANTATION pert ara ghee ‘Wonca th Foren So Prete
Slide 5: Initiation of Phase II and II/III Clinical Trials
Initiation of Phase II and II/III Clinical Trials By the end of 2019 Enlivex plans, subject to regulatory approvals, to initiate two clinical trials with Allocetra™ for the complications post bone marrow transplantations: (i) Phase II/III for prevention of complications post bone marrow transplantat
Slide 6: % Survival in CLP sepsis model
‘% Survival 100 80 60 40 20 25 ‘=CLP (cecum ligation and puncture) only CLP + Ertapenem'+ vehicle ‘CLP + Ertapenem'+ Allocetra-OTS r=20_pco0o1 so 7510025150175 200 Hours post CLP (Sepsis Induction)
Slide 7: Clinical Score Correlates to Survival in CLP-Induced Sepsis Model
CLINICAL SCORE CORRELATES TO SURVIVAL IN CLP-NDUCED SEPSIS MODEL 00 20 40 60 80 100 120 5 140 160 ‘linical Score: 180 200 “cecal enon ad puncte (LP ony eee tpenems Haran 23 30 48 S155 73 97 120 126 145 168 Hours post CLP
Slide 8: Ex vivo (CLP) preclinical data - Cytokine Storm
‘evvivo (CLP) preciinical data ~ Cytokine Storm: ‘Within 24 Hours From Sepsis Induction ilpcarisri ravens UiconTRCILED SIGNALING LEVELS (CYTOKINE STORM) POST SEPSIS INDUCTION, LEADING TO INCREASED SURVIVAL
Slide 9: In vivo (CLP) preclinical data - Cytokine Storm
levvivo (CLP) preciinical data ~ Cytokine Storm: ‘Within 24 Hours From Sepsis Induction (ooRTRAT VENTS UNCONTROLLED SIGNALING LEVELS (CYTOMNE STORM) POST ‘SEPSIS INDUCTION, LEADING TO INCREASED SURVIVAL
Slide 10: In-Vivo (CLP Sepsis) Preclinical Data - Dose Increases Survival
‘Survival IN-VIVO (CLP SEPSIS) PRECLINICAL DATA ~ DOSE INCREASES SURVIVAL 1100 80 60 40 20 0 2 «4 «6 ©6800 ago 160 180 Hours post CLP (Sepsis Induction) te (cca! gation ane puncture) oy cr + Enapenam + Alocetr-OTS-1X10°6
Slide 11: Initiation of Phase II in Sepsis
Initiation of Phase II in Sepsis Enlivex is planning to initiate a randomized, multi-center, vehicle-controlled, comparative, open-label, study evaluating safety and efficacy of Allocetra™-OTS for the prevention of organ dysfunction in patients with sepsis during the second quarter of 2019. This stu
Slide 12: Management Following the Merger
Description of Property and Facilities Employees Liquidity and Capital Resources It Legal Proceedings Management Following the Merger Executive Officers and Directors Termination of Current Executive Officers and Directors of Bioblast The employment of the current executive officers of Bioblast is e
Bioblast Pharma — Merger or Acquisition (December 2018) on 6ix